Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CISD1 | Q9NZ45 | 4/20 | 0.71 |
| ▸ | MAOB | P27338 | 2/20 | 0.71 |
| ▸ | MAOA | P21397 | 1/20 | 0.71 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.66 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | DUSP22 | Q9NRW4 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | CFTR | P13569 | 2/20 | 0.60 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24217823 | 0.87 | CISD1 (0.70) | CISD1MAOBMAOAPTPN12PTPN22 | |
| SCHEMBL3757080 | 0.85 | CISD1 (0.63) | CISD1MAOBMAOAPOLBMAPT | |
| SCHEMBL3757078 | 0.85 | CISD1 (0.63) | CISD1MAOBMAOAPOLBMAPT | |
| SCHEMBL17397856 | 0.84 | CISD1 (0.73) | CISD1MAOBMAOAPOLBMAPT | |
| SCHEMBL17397857 | 0.84 | CISD1 (0.73) | CISD1MAOBMAOAPOLBMAPT | |
| SCHEMBL17397858 | 0.84 | CISD1 (0.73) | CISD1MAOBMAOAPOLBMAPT | |
| SCHEMBL12333891 | 0.83 | CISD1 (1.00) | CISD1MAOBMAOAPOLBMAPT | |
| SCHEMBL11778921 | 0.83 | CISD1 (1.00) | CISD1MAOBMAOAPOLBMAPT | |
| SCHEMBL10801539 | 0.83 | CISD1 (1.00) | CISD1MAOBMAOAPOLBMAPT | |
| SCHEMBL1125306 | 0.82 | CISD1 (0.75) | CISD1MAOBMAOAMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024944-A1 | COMPOUNDS TARGETING MUTANT CALRETICULIN | MYELOPRO DIAGNOSTICS AND RESEARCH GMBH (AT) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024944-A1 | COMPOUNDS TARGETING MUTANT CALRETICULIN | CALR, MCL1, CALD1 | CISD1 388/4885MAOB 4787/4885MAOA 4831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.